Brief Title
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
Official Title
S0309, Myeloma Specimen Repository Protocol, Ancillary
Brief Summary
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer
to study in the laboratory may help doctors find better ways to ways to treat the cancer.
PURPOSE: The purpose of this study is to collect and store blood and bone marrow samples from
patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia,
amyloidosis, and monoclonal gammopathy of undetermined significance to be tested in the
laboratory.
Detailed Description
OBJECTIVES:
- Maintain and expand tissue repositories of myeloma specimens from uniformly treated
Southwest Oncology Group (SWOG) patients with multiple myeloma, smoldering myeloma,
Waldenstrom's macroglobulinemia, amyloidosis, or monoclonal gammopathy of undetermined
significance.
- Utilize scientific information generated from intergroup and collaborative studies to
assist the SWOG Myeloma Committee in the development of new and more effective treatment
regimens for these patients.
OUTLINE: Patients receive treatment as directed by the treatment protocols on which they are
registered. Specimens of blood and/or marrow are submitted to the Myeloma Repository. The
status of the patient (e.g., pre-study, post-remission, or relapse) will be recorded prior to
specimen collection.
PROJECTED ACCRUAL: Not specified
Study Type
Observational
Primary Outcome
Maintenance and expansion of tissue repositories of myeloma specimens from uniformly treated SWOG patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, or monoclonal gammopathy of undetermined significance
Condition
Multiple Myeloma
Intervention
biologic sample preservation procedure
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
190
Start Date
November 2003
Completion Date
November 2010
Primary Completion Date
November 2010
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of 1 of the following:
- Multiple myeloma
- Smoldering myeloma
- Waldenstrom's macroglobulinemia
- Amyloidosis
- Monoclonal gammopathy of undetermined significance
- Must be currently registered on a Southwest Oncology Group-coordinated treatment study
(SWOG or Intergroup)
- Must have pretreatment specimens to submit to this study
- No cytogenetic samples
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Gender
All
Ages
N/A - N/A
Accepts Healthy Volunteers
No
Contacts
Joshua Espstein, DSC, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT00919139
Organization ID
S0309
Secondary IDs
S0309
Responsible Party
Sponsor
Study Sponsor
Southwest Oncology Group
Collaborators
National Cancer Institute (NCI)
Study Sponsor
Joshua Espstein, DSC, Study Chair, University of Arkansas
Verification Date
April 2015